(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

RECEIVED
FEB 20 2002
TECH CENTER 1600/2900

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/782,587
	Filing Date	February 12, 2001
	First Named Inventor	Anders Hjelholt Pedersen
(Use as many sheets as necessary)	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	0212us310

OIPE FEB 14 2002 JC14 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
RT	AA	4,784,950		Hagen *et al.*	11/15/1998	
	AB	4,904,584		Shaw	02/27/1990	
	AC	5,041,376		Gething *et al.*	08/20/1991	
	AD	5,180,583		Hedner	01/19/1993	
	AE	5,225,537		Foster	07/06/1993	
	AF	5,288,629		Berkner	02/22/1994	
	AG	5,460,950		Barr *et al.*	10/24/1995	
	AH	5,580,560		Nicolaisen *et al.*	12/03/1996	
	AI	5,648,254		Mulvihill *et al.*	07/15/1997	
	AJ	5,824,634		Merchant	10/20/1998	
	AK	5,891,843		Turecek *et al.*	04/06/1999	
	AL	5,965,425		Barr *et al.*	10/12/1999	
	AM	5,986,079		Barr *et al.*	11/16/1999	
	AN	6,013,620		Turecek *et al.*	01/11/2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
RT	AO	EP	0 370 205 A2 ✓		Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	AP	EP	0 512 011 B1 ✓		Immuno Aktiengesellschaft	11/11/1992		
	AQ	WO	88/10295 ✓		Novo Industri A/S *et al.*	12/29/1988		
	AR	WO	91/11514 ✓		Zymogenetics, Inc.	08/08/1991		
	AS	WO	92/15686 ✓		Zymogenetics, Inc., *et al.*	09/17/1992		
	AT	WO	96/00577 ✓		COR Therapeutics, Inc.	01/11/1996		

AUFOREIGN PATENT DOCUMENTS

Examiner Signature	R.T Teller	Date Considered	8/11/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	**09/782,587**
Filing Date	**February 12, 2001**
First Named Inventor	**Anders Hjelholt Peders n**
Group Art Unit	**1645**
Examiner Name	**Unassigned**
Attorney Docket Number	**0212us310**

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
RT	AU	WO	98/32466		Polymasc Pharmaceuticals Plc	07/30/1998		
	AV	WO	98/35026		Novo Nordisk A/S	08/13/1998		
	AW	WO	99/03498		Novo Nordisk A/S	01/28/1999		
	AX	WO	99/03887		Bolder Biotechnology, Inc.	01/28/1999		
	AY	WO	99/20767		Regents of the University of Minnesota	04/29/1999		
	AZ	WO	99/66031		Baxter Aktiengesellschaft	12/23/1999		
	BA	WO	00/26230		Novo Nordisk A/S	05/11/2000		
	BB	WO	00/26354		Novo Nordisk A/S	05/11/2000		
	BC	WO	00/28065		Novo Nordisk A/S	05/18/2000		
	BD	WO	00/54787		The Children's Hospital of Philadelphia *et al.*	09/21/2000		
	BE	WO	00/66753		Regents of the University of Minnesota	11/09/2000		
	BF	WO	01/83725 A1		Novo Nordisk A/S	11/08/2001		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
RT	BG	Bharadwaj, D., *et al.*, "Factor VII Central—A Novel Mutation in the Catalytic Domain that Reduces Tissue Factor Binding, Impairs Activation by Factor XA, and Abolishes Amidolytic and Coagulant Activity," *J. Biological Chemistry* 271(48):30685-30691 (1996)	
	BH	Bjoern, S., *et al.*, "Human Plasma and Recombinant Factor VII – Characterization of *O*-Glycosylations at Serine Residues 52 and 60 and Effects of Site-Directed Mutagenesis of Serine 52 to Alanine," *J. Biological Chemistry* 266(17):11051-11057 (1991)	

Examiner Signature	R.T Eller	Date Considered	8/11/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/782,587**
	Filing Date	**February 12, 2001**
	First Named Inventor	**Anders Hjelh It Peders n**
	Group Art Unit	**1645**
	Examiner Name	**Unassigned**
(use as many sheets as necessary)	Attorney Docket Number	**0212us310**

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
RT	BI	Chang, J-Y., *et al.*, "Replacing the First Epidermal Growth Factor-like Domain of Factor IX with That of Factor VII Enhances Activity In Vitro and in Canine Hemophilia B," *J. Clin. Invest.* 100(4):886-892 (1997)	
	BJ	Chang, Y-J., *et al.*, "Engineered Recombinant Factor VII Q^{217} Variants with Altered Inhibitor Specificities," *Biochemistry* 38:10940-10948 (1999)	
	BK	Kemball-Cook, G., *et al.*, "Coagulation Factor VII Gln^{100}→Arg—Amino Acid Substitution at the Epidermal Growth Factor 2-Protease Domain Interface Results in Severely Reduced Tissue Factor Binding and Procoagulant Function," *J. Biological Chemistry* 273(14):8516-8521 (1998)	
	BL	Dickinson, C.D., *et al.*, "Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor," *J. Biological Chemistry* 272(32):19875-19879 (1997)	
	BM	Dickinson, C.D., *et al.*, "Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa," *Proc. Natl. Acad. Sci. USA* 93:14379-14384 (1996)	
	BN	Huang, Q., *et al.*, "Substrate Recognition by Tissue Factor-Factor VIIa – Evidence for Interaction of Residues Lys ^{165} and Lys ^{166} of Tissue Factor with the 4-Carboxyglutamate-Rich Domain of Factor X," *J. Biological Chemistry* 271(36):21752-21757 (1996)	
	BO	Iino, M., *et al.*, "Functional Consequences of Mutations in Ser-52 and Ser-60 in Human Blood Coagulation Factor VII," *Archives of Biochemistry and Biophysics* 352(2):182-192 (1998)	
	BP	Jin, J., *et al.*, "Factor VIIa's First Epidermal Growth Factor-like Domain's Role in Catalytic Activity," *Biochemistry* 38:1185-1192 (1999)	
	BQ	Kelly, C.R., *et al.*, "Ca^{2+} Binding to the First Epidermal Growth Factor Module of Coagulation Factor VIIa Is Important for Cofactor Interaction and Proteolytic Function," *J. Biological Chemistry* 272(28):17467-17472 (1997)	

Examiner Signature	R.Tella	Date Considered	8/11/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10/96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/782,587
	Filing Date	February 12, 2001
	First Named Inventor	Anders Hjelh It Pedersen
	Group Art Unit	1645
	Examiner Name	Unassigned
(use as many sheets as necessary)	Attorney Docket Number	0212us310

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
RT	BR	Leonard, B.J.N., *et al.*, "Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII," *J. Biological Chemistry* 275(45):34894-34900 (2000)	
	BS	Persson, E., "Characterization of the interaction between the light chain of factor VIIa and tissue factor," *FEBS Letters* 413:359-363 (1997)	
	BT	Persson, E., *et al.*, "Site-directed mutagenesis but not γ-carboxylation of Glu-35 in factor VIIa affects the association with tissue factor," *FEBS Letters* 385:241-243 (1996)	
	BU	Persson, E., *et al.*, "Ca^{2+} Binding to the First Epidermal Growth Factor-like Domain of Factor VIIa Increases Amidolytic Activity and Tissue Factor Affinity," *J. Biological Chemistry* 272(32):19919-19924 (1997)	
	BV	Petersen, L.C., *et al.*, "Binding of Zn^{2+} to a Ca^{2+} loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor," *Protein Science* 9:859-866 (2000)	
	BW	Petrovan, R.J., *et al.*, "Role of Residue Phe^{225} in the Cofactor-Mediated, Allosteric Regulation of the Serine Protease Coagulation Factor VIIa," *Biochemistry* 39:14457-14463 (2000)	
	BX	Ruf, W., *et al.*, "Importance of Factor VIIa Gla-Domain Residue Arg-36 for Recognition of the Macromolecular Substrate Factor X Gla-Domain," *Biochemistry* 38:1957-1966 (1999)	
	BY	Shah, A.M., *et al.*, "Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII," *Proc. Natl. Acad. Sci. USA* 95:4229-4234 (1998)	
	BZ	Shobe, J., *et al.*, "Macromolecular Substrate Affinity for the Tissue Factor-Factor VIIa Complex is Independent of Scissile Bond Docking," *J. Biological Chemistry* 274(34):24171-24175 (1999)	
	CA	Shobe, J., *et al.*, "Regulation of the Catalytic Function of Coagulation Factor VIIa by a Conformational Linkage of Surface Residue Glu 154 to the Active Site," *Biochemistry* 38:2745-2751 (1999)	

Examiner Signature	R.T.	Date Considered	8/11/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.